Physician profile
Daniel Gilbert
NPI 1053632091
$11,535.78
in general payments reported to CMS, 2019-2025
37 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,733 · 2020: $322 · 2021: $2,779 · 2022: $792 · 2023: $919 · 2024: $584 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,648 · Travel and Lodging: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,648.24 |
| Travel and Lodging | $262.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,753.94 | 2019-2023 | Da Vinci Surgical System |
| Ethicon INC. | $2,430.72 | 2021 | |
| Boston Scientific Corporation | $796.65 | 2019-2024 | Solyx Sis System |
| Abbvie INC. | $335.15 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $315.54 | 2024-2025 | Adstiladrin |
| Neotract INC. | $265.44 | 2019-2020 | |
| Allergan, INC. | $241.73 | 2019 | |
| Calyxo, INC. | $224.02 | 2024-2025 | Cvac Aspiration System |
| Caldera Medical, INC | $190.99 | 2021 | |
| Olympus America INC. | $187.38 | 2019-2023 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $172.80 | 2025 | |
| Progenics Pharmaceuticals, INC. | $156.77 | 2024-2025 | |
| Pfizer INC. | $124.73 | 2024-2025 | |
| Urogen Pharma, INC. | $119.04 | 2022-2025 | |
| Janssen Biotech, INC. | $116.36 | 2019-2025 | Erleada |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $114.98 | 2019 | |
| Coloplast Corp | $92.98 | 2023-2025 | Altis |
| Telix Pharmaceuticals | $84.23 | 2023-2024 | Illuccix |
| Medtronic, INC. | $78.29 | 2021-2025 | Altaviva |
| Astellas Pharma US INC | $75.59 | 2019-2025 | Xtandi, Myrbetriq |
| Agiliti Surgical, INC. | $69.69 | 2023 | Trinity |
| Dendreon Pharmaceuticals LLC | $68.16 | 2019-2025 | Provenge |
| Endo USA, INC. | $67.69 | 2024-2025 | Xiaflex, Aveed |
| Teleflex LLC | $66.00 | 2023-2025 | Barrigel, Urolift |
| Laborie Medical Technologies Corp. | $65.62 | 2022-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Tolmar, INC. | $39.32 | 2025 | Eligard, Jatenzo |
| Novartis Pharmaceuticals Corporation | $36.51 | 2025 | |
| Bioprotect Medical, INC. | $33.32 | 2025 | Bioprotect Balloon Implant System |
| C. R. Bard, INC. & Subsidiaries | $31.73 | 2020 | |
| Bard Access Systems, INC. | $30.25 | 2019 | |
| Myriad Genetic Laboratories, INC. | $24.60 | 2023 | Prolaris |
| Koelis INC. | $24.20 | 2023 | |
| 180 Medical, INC. | $23.62 | 2022 | |
| Antares Pharma, INC. | $23.14 | 2025 | Xyosted |
| Blue Earth Diagnostics | $21.69 | 2025 | Posluma |
| Immunitybio, INC. | $16.63 | 2025 | |
| Amgen INC. | $16.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.